Kampala Regional Mechanism for Reaching and Sustaining Epidemic Control in the Republic of Uganda under the President's Emergency Plan for AIDS Relief (PEPFAR) | CDC RFA GH22 2226

Opportunity Information: Apply for CDC RFA GH22 2226

The Kampala Regional Mechanism for Reaching and Sustaining Epidemic Control in the Republic of Uganda under PEPFAR is a CDC-led funding opportunity (CDC RFA GH22 2226) structured as a cooperative agreement, meaning the recipient is expected to work closely with CDC through substantial programmatic involvement and oversight. The program is focused on Kampala Region and is designed to accelerate and then maintain HIV epidemic control by supporting a full package of HIV and TB prevention, care, and treatment services. Although the notice lists an award ceiling for Year 1 as "0 (none)," CDC indicates it anticipates approximately USD 30,000,000 in total funding for Year 1, contingent on available funds, with the expectation of making one award.

At the core of the opportunity is expanding and improving comprehensive HIV service delivery with a strong emphasis on finding people who are not yet diagnosed and linking them to care quickly. The case-finding strategy is especially aimed at groups that are often harder to reach or may have lower testing and treatment uptake, including men, young people, and key populations. Once identified, the program supports the full continuum of HIV care and treatment, including rapid initiation and ongoing antiretroviral therapy (ART) services, alongside routine monitoring to ensure people remain engaged in care and achieve viral suppression.

TB services are explicitly integrated, reflecting the close relationship between TB and HIV outcomes. The supported activities include TB prevention, diagnosis, and treatment, which typically involves strengthening screening among people living with HIV, improving diagnostic capacity and referral pathways, and ensuring effective treatment initiation and follow-up. This HIV/TB integration is intended to reduce TB-related illness and death, which remains a major threat to people with HIV when TB is not detected early or treated effectively.

The opportunity also prioritizes prevention services that reduce new infections and improve maternal and child outcomes. This includes prevention of mother-to-child transmission (PMTCT) programming to ensure pregnant and breastfeeding women receive timely testing, treatment, and follow-up care, and that exposed infants receive appropriate services. It also includes voluntary medical male circumcision (VMMC) as a proven prevention intervention, and HIV pre-exposure prophylaxis (PrEP) for people at substantial risk of acquiring HIV, with the expectation that delivery models are practical, accessible, and linked to ongoing adherence support and follow-up.

A notable program element is attention to advanced HIV disease (AHD), which focuses on people who present late to care or return to care with severe immunosuppression. Managing AHD generally requires more intensive clinical and laboratory support, stronger triage and referral systems, and availability of essential commodities and diagnostics to reduce mortality. Alongside this, the notice highlights integrating non-communicable disease (NCD) services with HIV care to make it more convenient for clients to receive multiple services in one setting. The intent is to move toward more people-centered models of care that reduce the burden of multiple clinic visits while improving overall health outcomes.

Laboratory and strategic information components are central to how the program measures progress and improves performance. The NOFO calls for support to laboratory services such as viral load (VL) testing, which is essential for confirming treatment success and identifying individuals who need enhanced adherence support or clinical intervention. It also references recency surveillance, which is used to better understand patterns of recent HIV infection and can guide targeting of prevention and case-finding strategies. The strategic information work would typically include strengthening data quality, reporting, analysis, and use of data for decision-making at facility, district, and regional levels.

Implementation is framed as a health systems strengthening effort rather than a stand-alone project. The recipient is expected to work closely with Uganda's Ministry of Health to build the capacity of Regional Referral Hospitals and district health structures for a decentralized and sustainable response. In addition, the program emphasizes collaboration with faith-based and community-based partners to improve service delivery in ways that are more responsive to client needs and better able to reach underserved communities.

The overarching expected outcome is measurable progress toward, and sustained achievement of, the global 95-95-95 targets: 95 percent of people living with HIV knowing their status, 95 percent of those diagnosed receiving ART, and 95 percent of those on ART achieving viral suppression. In practice, this means the award is oriented toward expanding access and coverage, improving quality of services, tightening linkage and retention in care, and using strong lab and data systems to verify results and continuously improve program performance. Eligibility is listed as unrestricted (open to any type of entity, subject to any clarifications in the full notice), and the opportunity was posted by HHS/CDC with an original application due date of February 28, 2022, submitted electronically by 11:59 pm ET.

• The Department of Health and Human Services, Centers for Disease Control - CGH in the health sector is offering a public funding opportunity titled "Kampala Regional Mechanism for Reaching and Sustaining Epidemic Control in the Republic of Uganda under the President's Emergency Plan for AIDS Relief (PEPFAR)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.067.
• This funding opportunity was created on Dec 30, 2021.
• Applicants must submit their applications by Feb 28, 2022 Electronically submitted applications must be submitted no later than 1159 pm ET on the listed application due date.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for CDC RFA GH22 2226

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: